nCounter® PanCancer
Immune Profiling Panel
Helping Your Research
Perform multiplex gene expression analysis in human or mouse with 770 genes from different immune cell types, common checkpoint inhibitors, CT antigens, and genes covering both the adaptive and innate immune response. The panel measures many features of the immune response to facilitate rapid development of clinical actionable gene expression profiles in the context of cancer immunotherapy.
- Comprehensive profiling of the immune response optimized for immuno-oncology research
- Identify tumor-infiltrating lymphocytes (TILs) for the tumor microenvironment
- Assess mechanistic pathway activity for single or combination studies
- Customizable with up to 55 additional user-defined genes with Panel Plus option
- Multi-analyte analysis with Vantage 3D™ Assays
Panel Selection Tool
Find the gene expression panel for your research with easy to use panel pro
Find Your Panel
Product Information
360 Series Product Comparison
Fully-annotated gene lists in Excel format are available for each of the 360 Panels. The table below compares the biology coverage of the 360 Panels across the tumor, microenvironment, and the immune response to that of the PanCancer Panels Collection.
Publications
A novel diagnostic approach for the classification of small B-cell lymphoid neoplasms based on the NanoString platform.
Small B-cell lymphoid neoplasms (SBCLNs) are a heterogeneous group of diseases characterized by malignant clonal proliferation of mature B-cells. However, the classification of SBCLNs remains a challenge, especially in cases where histopathological analysis is unavailable or those with atypical laboratory findings or equivocal pathologic data.
Remodeling of the tumor microenvironment via disrupting Blimp1(+) effector Treg activity augments response to anti-PD-1 blockade.
BACKGROUND: Accumulation of Foxp3(+) regulatory T (Treg) cells in the tumor often represents an important mechanism for cancer immune evasion and a critical barrier to anti-tumor immunity and immunotherapy. Many tumor-infiltrating Treg cells display an activated phenotype and express the transcription factor Blimp1.
Expression of CIB1 correlates with colorectal liver metastases but not with peritoneal carcinomatosis.
Background: Molecular differences in colorectal cancer (CRC) are associated with the metastatic route. Patient survival is mainly driven by metastatic spread thus it is imperative to understand its key drivers to develop biomarkers for risk stratification, follow-up protocols and personalized therapy.
Contact Us
Have questions or simply want to learn more?
Contact our helpful experts and we’ll be in touch soon.